Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma Clinical Trial

Official title:

A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients ≤ 70 Years Old With Smoldering Multiple Myeloma (SMM) With High Risk of Progression to Symptomatic Myeloma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02415413
• Other study ID #: GEM-CESAR
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 2015
• Est. completion date: June 2027

Study information

• Verified date: September 2022
• Source: PETHEMA Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

Description:

This clinical trial is a multicenter Phase II study designed to evaluate the efficacy and toxicity of an intensive therapeutic approach in 90 patients with asymptomatic high risk multiple myeloma (SMM). 1. - Patients will receive an induction treatment consisting of 6 cycles of carfilzomib, lenalidomide and low-dose dexamethasone (KRd): patients will receive carfilzomib 20-36 mg/m2 IV on days 1, 2, 8, 9, 15 and 16; with oral lenalidomide 25 mg daily on days 1-21, subsequently there will be a rest period of a week (from day 22 to day 27). Moreover, oral dexamethasone 40mg daily will be administered weekly (days 1, 8, 15 and 22). 2. - Following the induction treatment, patients will receive high-dose (200 mg/m2) melphalan-based treatment administered via the intravenous route followed by peripheral blood stem cell transplantation (HDT-ASCT). 3. - The consolidation treatment will consist of 2 cycles of KRd, with the same doses and scheduled of the induction treatment. 4. - Maintenance treatment: all patients, without progression to symptomatic multiple myeloma or toxicity requiring discontinuation of the trial, will receive maintenance treatment during 24 cycles. This maintenance treatment comprises the administration of lenalidomide 10mg on days 1-21, followed by a rest period of 1 week, with the weekly administration of dexamethasone 20mg. Treatment will be administrated until the end of the maintenance, although patients will continue in the trial. If biological progression is observed following the discontinuation of the treatment, lenalidomide and dexamethasone will be reinstituted in order to control the disease again. Lenalidomide 10 mg will be administrated on days 1-21 combined with dexamethasone 20mg on days 1, 8, 15 and 22. All patients will be monitored for asymptomatic disease progression and to collect data regarding on overall survival (OS).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: June 2027
• Est. primary completion date: July 5, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• In the investigator's opinion, the patient must be able to fulfill all the clinical trial requirements.
• The patient must voluntarily sign the informed consent before any study procedure that is not part of the standard of care for these patients is performed, with the patient's knowledge that he/she may withdraw from the study at any time, without prejudice to his/her future care.
• The patient must be aged between 18 and 70 years, and eligible to receive high-dose therapy and autologous peripheral blood stem cell transplant.
• The patient must be diagnosed with smoldering multiple myeloma at high risk of progressing to symptomatic multiple myeloma, or at ultra high risk of progression to

symptomatic disease, defined by:

• smoldering multiple myeloma at high risk of progression to symptomatic disease:

Bone marrow infiltration with plasma cells (PCs) greater than or equal 10% and presence of a monoclonal component, immunoglobulin G (IgG) greater than3 g/dL or IgA greater than 2 g/dL or Bence Jones proteinuria greater than 1 g/24h and absence of lytic lesions, hypercalcemia, renal failure (creatinine less than 2 mg/dL) and anemia (hemoglobin greater than 10 gr/dL or not 2 gr/dL below the lower limit of normal). Bone marrow infiltration with PCs greater than or equal 10% OR IgG greater than 3 g/dL or immunoglobulin A (IgA) greater than 2 g/dL or Bence Jones proteinuria greater than 1g/24h (but not both together) and always in the absence of lytic lesions, hypercalcemia, renal failure and anemia. These patients may be included in the study if they meet the following additional criteria: A percentage of phenotypically aberrant plasma cells (PCs) within the bone marrow (BM) PC compartment (aPC/ BM PC) greater than or equal 95% and immunoapheresis, defined as a reduction in the levels of 1 or 2 immunoglobulin (Igs) of more than 25% compared with the normal values of the corresponding Ig.

• smoldering multiple myeloma at ultra high risk of progression to symptomatic disease:

Presence of more than 1 focal lesion in MRI (ideally whole body MRI). Infiltration in the BM equal or higher than 60%. Ratio of involved/uninvolved serum Friend leukemia cell (FLC) higher than 100.

• The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status less than 2.
• The patient must be able to attend the scheduled visits.
• Women of childbearing potential must have a negative pregnancy test (serum or urine) within the 14 days before the starting the study drug. In addition, sexually active women must agree to use contraceptive methods (hormone contraceptives [oral, injectable or implanted], tubal ligation, intrauterine device, barrier contraceptives with spermicide or have a vasectomised partner) while receiving the study drug. Women of childbearing potential must agree to undergo pregnancy tests every 4 weeks while receiving the study drug (every 14 days for women with irregular menstrual cycles) and 4 weeks after the last dose of study drug.

Exclusion Criteria:

• Any physical condition or psychiatric disorder that would prevent the patient from signing or understanding the informed consent form.
• Previous treatment for smoldering multiple myeloma.
• Pregnancy or breastfeeding.
• Presence of lytic lesions, anemia, renal failure or hypercalcemia.
• Any of the following laboratory abnormalities:

Absolute neutrophil count (ANC) less than 1,000/mm3 Platelet count less than 75,000/mm3. Serum GOT or glutamic pyruvic transaminase (GPT) greater than 3 x upper limit of normal Serum total bilirubin greater than 2 x upper limit of normal

• Prior history of neoplasm other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been disease-free for > 5 years.
• Major surgery within 4 weeks before inclusion in the study.
• Known active infection by human acquired immunodeficiency virus, B or C hepatitis virus.
• Any investigational drug within 30 days before inclusion in the study.
• Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrolment.
• Unstable angina or myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.
• Uncontrolled hypertension or uncontrolled diabetes.
• Significant neuropathy (Grades 3?4, or Grade 2 with pain) within 14 days prior to enrollment.
• Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).
• Contraindication to any of the required concomitant drugs or supportive treatments, including intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
• Left ventricular ejection fraction (LVEF) less than 40
• Pulmonary hypertension

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Smoldering Multiple Myeloma

Intervention

Drug:
• carfilzomib

• Lenalidomide

• Dexamethasone

• Melphalan

Locations

Country	Name	City	State
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital Universitari Germans Trias i Pujol	Barcelona
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Universitario Morales Meseguer	Murcia
Spain	Hospital Universitario Central de Asturias	Oviedo
Spain	Clínica Universidad de Navarra	Pamplona
Spain	Hospital de Son Llàtzer	Plama De Mallorca
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Hospital Universitario Reina Sofía	Sevilla
Spain	Hospital Universitario Virgen del Rocío	Sevilla
Spain	Hospital Universitario de Canarias	Tenerife
Spain	Hospital Clínico Universitario de Valencia	Valencia
Spain	Hospital Universitario Doctor Peset	Valencia
Spain	Hospital Clínico Universitario Lozano Blesa	Zaragoza

Sponsors (3)

Lead Sponsor	Collaborator
PETHEMA Foundation	Amgen, Celgene Corporation

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT	Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT	4 months
Secondary	Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance	Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance	up to 24 weeks
Secondary	Efficacy- Months to progression free survival	Months to progression free survival	60 months
Secondary	Efficacy -Months to overall survival	Months to overall survival	60 months
Secondary	Relapse or progression patterns in the group of patients requiring a rescue therapy after june 2020.	Relapse or progression patterns after first line treatment with KRd->PBPCT->KRd->Rd, in the group of patients requiring a rescue therapy after june 2020.	Up to 84 months (from june 2020)
Secondary	Response rate of rescue therapy in the group of patients requiring a rescue therapy after june 2020.	Response rate achieved with daratumumab, pomalidomide and dexamethasone (DPd) as rescue therapy, by evaluating all response categories, including immunophenotypic response, sCR, CR, VGPR, PR and SD.	Up to 84 months (from june 2020)
Secondary	Progression Free Survival (PFS) and Overall Survival (OS) from the date of relapse / progression of disease	PFS and OS from the date of relapse / progression of disease, in the group of patients requiring a rescue therapy.	Up to 84 months (from june 2020)
Secondary	Biological studies in the group of patients requiring a rescue therapy.	Phenotypic and molecular assessment of the tumor clone that appears in the moment of relapse or disease progression (DP), and comparison against the tumor clone characterized at the moment of inclusion in the first part of the trial.	Up to 84 months (from june 2020)
Secondary	Study of patient immune profile in the group of patients requiring a rescue therapy.	Assessment of patient immune profile at the moment of inclusion in this modification, and assessment of evolution under DPd treatment.	Up to 84 months (from june 2020)
Secondary	Study of patient immune profile depending on type of relapse, in the group of patients requiring a rescue therapy.	Assessment of immune profile at the moment of inclusion in patients in biochemical relapse vs. those in symptomatic relapse.	Up to 84 months (from june 2020)